We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » RANBAXY TO CONDUCT NEW GENERIC HIV DRUG STUDIES
RANBAXY TO CONDUCT NEW GENERIC HIV DRUG STUDIES
November 16, 2004
Ranbaxy Laboratories plans to conduct new clinical studies in North America for its generic antiretroviral fixed-dose combination (FDC) HIV treatments to definitively establish their bioequivalence, company officials said.